P54 Combined exposure to vapors, gases, dusts, fumes and tobacco smoke increases the risk of asthma symptoms

BackgroundOccupational exposure to vapors, gases, dusts and fumes (VGDF) is known to increase the prevalence of asthma symptoms. Less is known about the prevalence of asthma symptoms if VGDF exposure is combined to smoking or environmental tobacco smoke exposure.ObjectiveTo test the hypothesis that...

Full description

Saved in:
Bibliographic Details
Published inThorax Vol. 76; no. Suppl 2; p. A96
Main Authors Hisinger-Molkanen, H, Pallasaho, P, Sovijarvi, A, Tuomisto, L, Andersen, H, Lindqvist, A, Backman, H, Langhammer, A, Ronmark, E, Lundback, B, Ilmarinen, P, Kankaanranta, H, Piirila, P
Format Journal Article
LanguageEnglish
Published London BMJ Publishing Group Ltd and British Thoracic Society 08.11.2021
BMJ Publishing Group LTD
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:BackgroundOccupational exposure to vapors, gases, dusts and fumes (VGDF) is known to increase the prevalence of asthma symptoms. Less is known about the prevalence of asthma symptoms if VGDF exposure is combined to smoking or environmental tobacco smoke exposure.ObjectiveTo test the hypothesis that combined exposure to VGDF and tobacco smoke would have an additive effect on the risk for being symptomatic in responders with physician diagnosed asthma.MethodsA random sample of 16 000 adults aged 20 to 69 years were invited to a postal survey on obstructive pulmonary diseases in Finland in 2016. Those who reported physician diagnosed asthma were included in the analysis and their reported VGDF exposure and smoking habits were analyzed. Being symptomatic was defined as an affirmative answer to three or more questions of asthma symptoms.Results8199 (51.5%) subjects responded. Of the responders, 831 reported physician-diagnosed asthma. 22.3% of asthmatics reported current smoking, 23.2% exposure to environmental tobacco smoke and 39.4% occupational exposure to VGDF. 14.0% reported combined exposure to environmental tobacco smoke and VGDF, and 10.2% exposure to VGDF and smoking. The prevalence of being symptomatic was increased in smokers (73.0% vs 58.0%, p=0.005) and in responders with occupational exposure to VGDF (75.2% vs 58.0%, p<0.001) compared to unexposed asthmatics. The highest prevalence estimates were seen in smokers with VGDF exposure (83.5% vs 58.0%, p<0.001) and in responders with exposure to both VGDF and environmental tobacco smoke (85.3% vs 58.0%, p<0.001) suggesting their additive effect on the prevalence of asthma symptoms. There was no difference in asthma medication use between responders with no exposure history, smokers or those with environmental tobacco smoke or occupational VGDF exposure.ConclusionOur results indicate an increased prevalence of asthma symptoms in adult asthmatics with exposure to VGDF and tobacco smoke. Asthmatics with exposure to both environmental tobacco smoke and VGDF had the highest prevalence estimates of asthma symptoms suggesting an additive effect. These results suggest the importance of prevention of occupational airborne exposures and smoking cessation in asthma treatment.
Bibliography:British Thoracic Society Winter Meeting 2021 Online, Wednesday 24 to Friday 26 November 2021, Programme and Abstracts
ISSN:0040-6376
1468-3296
DOI:10.1136/thorax-2021-BTSabstracts.164